Tool: CRAVAT: a web tool to annotate and analyze cancer variants
gravatar for Collin
4.3 years ago by
United States
Collin700 wrote:

CRAVAT provides high-throughput services for researchers to annotate and prioritize small-scale exome variants and genes discovered in normal tissues and cancers. Annotations include TARGET drug associations, 1000 Genomes, Exome Variant Server and Exome Aggregation Consortium (ExAC) minor allele frequencies by population.  Variant zygosity, pileup coverage and variant allele frequencies are provided when users submit vcf files.  Cancer-specific annotations include COSMIC mutation frequencies by tumor type, Vogelstein/Kinzler oncogene/tumor suppessor gene assignments and PubMed hits. Variant- and gene-level annotations and bioinformatic scores are provided to enable interpretation and prioritization of variants identified in sequencing studies, including frameshift and in-frame insertions/deletions, splice site, missense and nonsense. Variants can be submitted either as a Variant Call File (vcf) or in a simple tab-delimited format, based on genome coordinates, by uploading through a graphical web interface or a RESTful web services API.

We have now released CRAVAT 4.0 Beta with a new interactive interface, sortable tabular views of results in worksheet format are enhanced with graphical displays that highlight significant properties of variants and genes, including protein-domain based lollipop displays and viewing variants on annotated human 3D protein structures and theoretical homology models.  For users interested in cancers, TCGA mutations from 31 cancer types in 1D and 3D, and statistically significant 3D mutation clusters can be viewed for each cancer type and for TCGA's Pan-cancer study of 12 tumor types.

You can find CRAVAT at, and additional help information at To beta test the new interactive viewer to explore exome variants in more depth, please contact the CRAVAT team by email at

ADD COMMENTlink modified 4.3 years ago • written 4.3 years ago by Collin700
Please log in to add an answer.


Use of this site constitutes acceptance of our User Agreement and Privacy Policy.
Powered by Biostar version 2.3.0
Traffic: 1649 users visited in the last hour